2026-08-10T01:28:16Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/227272024-11-28T21:00:43Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967
00925njm 22002777a 4500
dc
Feng, Xiaojun
author
Soldevila Verdeguer, Carla
author
Jafari, Samineh
author
Memariani, Zahra
author
Tewari, Devesh
author
Annunziata, Giuseppe
author
Barrea, Luigi
author
Hassan, Sherif T. S
author
Smejkal, Karel
author
Malanik, Milan
author
Sychrova, Alice
author
Barreca, Davide
author
Ziberna, Lovro
author
Mahomoodally, Mohamad Fawzi
author
Zengin, Gokhan
author
Xu, Suowen
author
Nabavi, Seyed Mohammad
author
Shen, Ai-Zong
author
2019
Cardiovascular and metabolic diseases (CVMD) are the leading causes of death worldwide, underscoring the urgent necessity to develop new pharmacotherapies. Berberine (BBR) is an eminent component of traditional Chinese and Ayurvedic medicine for more than 2000 years. Recently, BBR has attracted much interest for its pharmacological actions in treating and/or managing CVMD. Recent discoveries of basic, translational and clinical studies have identified many novel molecular targets of BBR (such as AMPK, SIRT1, LDLR, PCSK9, and PTP1B) and provided novel evidences supporting the promising therapeutic potential of BBR to combat CVMD. Thus, this review provides a timely overview of the pharmacological properties and therapeutic application of BBR in CVMD, and underlines recent pharmacological advances which validate BBR as a promising lead drug against CVMD.
Feng X, Sureda A, Jafari S, Memariani Z, Tewari D, Annunziata G, et al. Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics. Theranostics. 2019;9(7):1923-51.
10.7150/thno.30787
1838-7640
Theranostics
http://hdl.handle.net/20.500.13003/17155
31037148
L627547235
2-s2.0-85065480668
https://hdl.handle.net/20.500.12105/22727
461767700008
Berberine
Cardiovascular diseases
Metabolic diseases
Targets
Therapeutics
Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics